| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2012: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Research Abstract |
In this study, we aimed to determine if cytokeratin 19 (CK19), a hepatic progenitor cell marker, can used as a CSC marker in HCC.
First, we transfected the CK19 promoter-driven enhanced green fluorescence protein gene into human HCC cell lines. Then we isolated CK19+ cells using fluorescence-activated cell sorting (FACS). Furthermore, xenotransplantation into non-obese diabetic/severe combined immunodeficiency mice revealed that CK19+ cells could reproduce themselves, differentiate into CK19- cells, and generate larger tumors at a higher frequency in vivo. These results indicated that CK19+ HCC cells possess CSC properties. And, immunohistochemistry analyses of 166 consecutive human HCC specimens resected at Kyoto University showed that CK19 expression is an independent predictor of postoperative recurrence.
|
